Jason Dengyuemed

Jason Dengyuemed added article Health
2026-03-13 02:52:17

A New ARB–Diuretic Combination Option: Telmisartan Hydrochlorothiazide Tablets Offer More Stable Blood Pressure Control for Hypertension
Globally, hypertension has become one of the most common chronic diseases, affecting more than 1 billion people. Long-term elevated blood pressure not only damages the heart, blood vessels, and kidneys, but also significantly increases the risk of serious cardiovascular events such as myocardial infarction, stroke, and heart failure. However, because hypertension often presents without...

0 Comments 0 Shares 255 Views 0 Reviews

Please log in to like, share and comment!
Jason Dengyuemed added article Health
2026-03-12 01:32:41

A Breakthrough in JAK Inhibitors: Baricitinib Brings New Hope to the Treatment of Autoimmune Diseases
Globally, autoimmune diseases such as rheumatoid arthritis (RA) affect the health of tens of millions of people. These conditions, caused by the immune system mistakenly attacking the body's own tissues, lead to chronic inflammation, joint destruction, and even disability, severely diminishing patients' quality of life. Although traditional disease-modifying antirheumatic drugs and biologics...

0 Comments 0 Shares 483 Views 0 Reviews

Please log in to like, share and comment!
Jason Dengyuemed added article Wellness
2026-02-28 09:44:51

China's Rare Disease Drugs: From "Follower" to Emerging Global Leader – 2026 Latest Observations
In February 2026, China's rare disease drug market once again takes center stage in the global pharmaceutical arena. According to the latest industry data, the global rare disease drug market reached approximately $78 billion in 2023, with the United States accounting for 35% and Europe 29%, while China has surged to the third position worldwide, holding about 15% market share. Even more...

0 Comments 0 Shares 699 Views 0 Reviews

Please log in to like, share and comment!
Jason Dengyuemed added article Health
2026-01-19 07:51:20

Akeso’s Ivonescimab (PD-1/VEGF Bispecific Antibody) Submits BLA to the FDA
On January 12, 2026, Summit Therapeutics announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ivonescimab, a PD-1/VEGF bispecific antibody developed by Akeso. The application seeks approval for ivonescimab in combination with chemotherapy as a second-line treatment for patients with locally advanced or metastatic non-squamous...

0 Comments 0 Shares 1089 Views 0 Reviews

Please log in to like, share and comment!
Jason Dengyuemed added article Health
2026-01-13 08:45:25

China's Innovative Medicines: Bringing New Hope to Global Patients
Imagine facing a diagnosis of advanced cancer or a chronic condition with limited options—then learning that breakthrough therapies from China are now reaching international markets, offering potentially more effective, accessible treatments. This is the reality unfolding in 2026, as Chinese biopharma accelerates from domestic innovation to global impact. The wave of innovative drug...

0 Comments 0 Shares 1091 Views 0 Reviews

Please log in to like, share and comment!
Jason Dengyuemed added article Health
2026-01-12 08:03:43

China's Innovative Drugs Going Global: A New Era for Worldwide Health in 2026
By HongKong DengYue Medicine The global pharmaceutical landscape is undergoing a profound transformation, and Chinese innovative drugs are at the forefront of this shift. In 2025, China's out-licensing (License-out) deals for innovative drugs reached a staggering total value of approximately $1,356.55 billion (around 9,483 billion RMB), with 157 transactions and upfront payments totaling $70...

0 Comments 0 Shares 1226 Views 0 Reviews

Please log in to like, share and comment!
Jason Dengyuemed added article Health
2026-01-09 07:33:27

Ivonescimab: Pioneering Progress in EGFR-Mutated Non-Squamous NSCLC Treatment
Edited by HongKong DengYue Medicine As we step into 2026, the landscape of cancer treatment continues to evolve, bringing rays of hope to patients worldwide who have long battled the uncertainties of lung cancer. Imagine being a patient diagnosed with EGFR-mutated non-squamous non-small cell lung cancer (NSCLC), having gone through the rigors of EGFR-TKI therapy only to face progression. The...

0 Comments 0 Shares 1162 Views 0 Reviews

Please log in to like, share and comment!
Jason Dengyuemed added article Health
2025-12-22 09:10:03

Explorando os Efeitos em Cascata da Operação Selada de Hainan nas Exportações Farmacêuticas da China
No panorama em constante evolução do comércio global, o setor farmacêutico da China está posicionado para transformações significativas, particularmente com recentes mudanças de política em regiões chave. Ao mergulharmos nas implicações da "operação selada" de Hainan – um movimento que...

0 Comments 0 Shares 1668 Views 0 Reviews

Please log in to like, share and comment!
Jason Dengyuemed added article Health
2025-12-03 08:46:18

China's Innovative Drug Export: Accelerating a New Era of Globalization
In the rapidly evolving pharmaceutical landscape of 2025, Chinese innovative drug companies are not just participating but leading on the international stage with remarkable speed and ambition. This surge is driven by a combination of technological advancements, supportive government policies, and strategic global partnerships. Over the past 24 hours alone, several pivotal developments have...

0 Comments 0 Shares 1732 Views 0 Reviews

Please log in to like, share and comment!
Jason Dengyuemed added article Health
2025-09-23 06:39:35

Ionis Launches Tryngolza™ (Olezarsen) for FCS With Positive Phase 3 Data and $595,000 Annual List Price
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the official U.S. launch of Tryngolza™ (olezarsen), a novel, once-monthly RNA-targeted therapy for familial chylomicronemia syndrome (FCS). The drug enters the market at an annual list price of $595,000, following its FDA approval in December 2024. First FDA-Approved Olezarsen Therapy for...

0 Comments 0 Shares 3185 Views 0 Reviews

Please log in to like, share and comment!

Connect Freelancing Platform